StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit

rezpegaldesleukinNeutral

AI Analysis

Summary

Nektar Therapeutics won a jury verdict of $90M against Eli Lilly in a three-year legal dispute over the termination of a collaboration agreement to co-develop rezpegaldesleukin, though the award was less than sought and the stock market reacted negatively to the outcome.

Outcome Details

Jury sided with Nektar in legal dispute; $90M verdict awarded, less than amount sought

Importance:4/10

Sentiment:

-0.20

litigationcollaboration terminationlegal disputestock reactionNektar TherapeuticsEli Lilly

Related Companies

$NKTR $LLY

Read the original article

Published by GEN - Genetic Engineering & Biotech News on September 27, 2026 7:05 PM

Read Original